| Size | Price | |
|---|---|---|
| 100mg | ||
| 500mg |
| Targets |
GSK-3β; CDK; JNK1 (IC50 = 0.8 μM); JNK2 (IC50 = 1.4 μM); JNK3 (IC50 = 1 μM)
|
|---|---|
| ln Vitro |
Indirubin-3′-oxime inhibits c-Jun phosphorylation in cerebellar granule neurons (CGNs) caused by potassium withdrawal and, in a dose-dependent manner, keeps CGNs from dying[1].
Indirubin-3′-oxime (IDR3O) (PC12 cells; 10 μM) considerable inhibition of the 6OHDA-induced reduction in nuclear localized MEF2D expression[2]. |
| ln Vivo |
Indirubin-3′-oxime (0.05 or 0.5 mg/kg; i.p.; daily for 2 or 10 weeks) increases the length of the tibia in mice without negatively altering the parameters of bone thickness[3].
|
| Animal Protocol |
Three-week-old C57BL/6 mice[3]
0.05 or 0.5 mg/kg I.p.; daily for 2 or 10 weeks |
| References |
|
| Additional Infomation |
Indirubin-3'-monoxime is a member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime. It has a role as an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor, an osteogenesis regulator, a neuroprotective agent and an anti-obesity agent. It is a member of oxindoles, a bisindole, a ring assembly, a ketoxime and an alkaloid.
|
| Molecular Formula |
C16H11N3O2
|
|---|---|
| Exact Mass |
277.085
|
| CAS # |
667463-82-3
|
| Related CAS # |
667463-82-3
|
| PubChem CID |
3707
|
| Appearance |
Brown to red solid
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
21
|
| Complexity |
405
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
FQCPPVRJPILDIK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H11N3O2/c20-16-13(9-5-1-3-7-11(9)18-16)15-14(19-21)10-6-2-4-8-12(10)17-15/h1-8,17-18,20H
|
| Chemical Name |
3-(3-nitroso-1H-indol-2-yl)-1H-indol-2-ol
|
| Synonyms |
Indirubin-3-oxime; IDR-3O; I3O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 55~100 mg/mL(198.4~360.7 mM)
Ethanol: ~55 mg/mL(~198.4 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
